Journal of Neurology

, Volume 253, Issue 9, pp 1154–1159

Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease

  • Kathy Dujardin
  • David Devos
  • Stéphane Duhem
  • Alain Destée
  • Rose-Marie Marié
  • Franck Durif
  • Lucette Lacomblez
  • Jacques Touchon
  • Pierre Pollak
  • Jean-Jacques Péré



The severe, cortical, cholinergic depletion accompanying Parkinson’s disease (PD) is considered as a highly probable correlate of cognitive and behavioural dysfunction. Recent studies have demonstrated that cholinesterase inhibitors (notably rivastigmine) are beneficial in patients suffering from dementia associated with PD (PDD). However, the primary efficacy variables used in such work came from scales designed for Alzheimer’s disease (AD), even though the cognitive symptoms in PD and AD dementia do not overlap completely. The aim of the present study (a double-blind, placebo-controlled clinical trial) was to determine the utility of the Mattis dementia rating scale - the most commonly used scale in PD patients - to assess the efficacy of a 24-week rivastigmine treatment.


Twenty-eight patients with PD, who constituted a subgroup of patients enrolled to the EXPRESS study (Emre et al, N Engl J Med 2004) participated in this study. They suffered from mild to moderately severe dementia (MMSE scores above 10 and below 24), with an onset of cognitive symptoms occurring at least two years after the diagnosis of PD. Patients were randomly assigned to treatment with rivastigmine (3 to 12 mg per day) or placebo. The Mattis dementia rating scale was administered to patients from six centres in France at the baseline and end-point visits.


Compared with placebo, a 24-week rivastigmine treatment led to a significant improvement in the overall score on the Mattis dementia rating scale (p = 0.031), with a trend towards a significant improvement in the “Attention” subscale score (p = 0.061). Correlation analysis showed that in the rivastigmine group, performance on the Mattis “Attention” and “Initiation” subscales appeared to contribute heavily to the improvement in the overall score. Moreover, the latter was also related to an improvement in activities of daily living and a reduction in behavioural disturbances.


By using the Mattis dementia rating scale (which comprises items that are sensitive to executive dysfunction), the present study confirmed that rivastigmine has a beneficial effect on cognitive function in PDD. Despite our study’s small sample size, the Mattis scale was able to detect this improvement and could thus be considered as an interesting outcome measure in further work.


cognitive dysfunction in PD mattis dementia rating scale dementia cholinesterase inhibitors 


  1. 1.
    Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60: 387–92PubMedCrossRefGoogle Scholar
  2. 2.
    Aarsland D, Mosimann UP, McKeith IG (2004) Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17:164–71PubMedCrossRefGoogle Scholar
  3. 3.
    Bak TH, Rogers TT, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR (2005) Cognitive bedside assessment in atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 76: 420–2PubMedCrossRefGoogle Scholar
  4. 4.
    Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, Dekosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–8PubMedCrossRefGoogle Scholar
  5. 5.
    Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis CA, Davis JG, Moore RY, Dekosky ST (2005) Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol Sep 2; [Epub ahead of print]Google Scholar
  6. 6.
    Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64: 1404–10PubMedGoogle Scholar
  7. 7.
    Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 18: 258–64PubMedCrossRefGoogle Scholar
  8. 8.
    Connelly PJ, Prentice NP, Fowler KG (2005) Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 76: 320–4PubMedCrossRefGoogle Scholar
  9. 9.
    Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol. 2: 229–37PubMedCrossRefGoogle Scholar
  10. 10.
    Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 351: 2509–18PubMedCrossRefGoogle Scholar
  11. 11.
    Fahn S, Elton RL, the members of the UPDRS Development Committee (1987) The Unified Parkinson’s disease rating scale In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds), Recent developments in Parkinson’s disease Vol. 2. Florham Park, NJ Macmillan healthcare pp 153–163Google Scholar
  12. 12.
    Gibb WRG, Lees A (1988) The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51: 745–752PubMedCrossRefGoogle Scholar
  13. 13.
    Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD (2003) Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand 108: 368–73PubMedCrossRefGoogle Scholar
  14. 14.
    Hofer SM, Piccinin AM, Hershey D (1996) Analysis of structure and discriminative power of the Mattis Dementia Rating Scale. J Clin Psychol. 52: 395–409PubMedCrossRefGoogle Scholar
  15. 15.
    Kaufer DI (2002) Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response. CNS Spectr 7: 742–50PubMedGoogle Scholar
  16. 16.
    Kaufer DI, Bohnen NI, Ivanco L, Hendrickson R, Lopresti B, Mathis CA, Moore RY, DeKosky ST (2005) Cholinergic Correlates of Cognitive and Neuropsychiatric Disturbances in Parkinson s Disease with and without Dementia. Neurology 64(6, suppl 1): A.137Google Scholar
  17. 17.
    Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol (Berl) 106: 83–8Google Scholar
  18. 18.
    Marson DC, Dymek MP, Duke LW, Harrell LE (1997) Subscale validity of the Mattis Dementia Rating Scale. Arch Clin Neuropsychol. 12: 269–75PubMedCrossRefGoogle Scholar
  19. 19.
    Mattis S (1976) Mental status examination for organic mental syndrome in the elderly patient In: Bellak L., Karasy T.E. (Eds) Geriatric Psychiatry New York Grune and Stratton pp 77–121Google Scholar
  20. 20.
    Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, Littlewood E, Myint P, Newby J, McKeith IG (2003) What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 18: 988–93PubMedCrossRefGoogle Scholar
  21. 21.
    Querfurth HW, Allam GJ, Geffroy MA, Schiff HB, Kaplan RF (2000) Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord 11: 314–21PubMedCrossRefGoogle Scholar
  22. 22.
    Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76: 934–9PubMedCrossRefGoogle Scholar
  23. 23.
    Smith GE, Ivnik RJ, Malec JF, Kokmen E, Tangalos E, Petersen RC (1994) Psychometric Properties of the Mattis Dementia Rating Scale. Assessment 1: 123–32PubMedGoogle Scholar
  24. 24.
    Wallin AK, Gustafson L, Sjogren M, Wattmo C, Minthon L (2004) Five-year outcome of cholinergic treatment of Alzheimer’s disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy Dement Geriatr Cogn Disord 18: 197–206PubMedCrossRefGoogle Scholar
  25. 25.
    Zgaljardic DJ, Foldi NS, Borod JC (2004) Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm 111: 1287–301PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  • Kathy Dujardin
    • 1
    • 8
  • David Devos
    • 1
  • Stéphane Duhem
    • 1
  • Alain Destée
    • 1
  • Rose-Marie Marié
    • 2
  • Franck Durif
    • 3
  • Lucette Lacomblez
    • 4
  • Jacques Touchon
    • 5
  • Pierre Pollak
    • 6
  • Jean-Jacques Péré
    • 7
  1. 1.Neurology and Movement Disorders UnitFaculty of Medicine and Lille University HospitalLilleFrance
  2. 2.Service de NeurologieCHU Côte de NacreCaenFrance
  3. 3.Service de NeurologieHôpital Gabriel MontpiedClermont-FerrandFrance
  4. 4.Fédération de NeurologieHôpital de la SalpetrièreParisFrance
  5. 5.Unité de Neurologie, Comportementale et DégénérativeCHU Gui-de-ChauliacMontpellierFrance
  6. 6.Service de NeurologieCHUGrenobleFrance
  7. 7.Novartis PharmaFrance
  8. 8.Centre Hospitalier UniversitaireHôpital SalengroLille CedexFrance

Personalised recommendations